Analysis of Transplant-eligible Patients (Pts) Who Received Front-line Daratumumab (DARA)-based Therapy for Treatment of Newly Diagnosed Multiple Myeloma (NDMM) With High-risk Cytogenetic Abnormalities (HRCA) in the GRIFFIN (AFT-29) and MASTER Studies
- Citation:
- Blood vol 140 (suppl 1) 10144–7
- Meeting Instance:
- ASH 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4081
- Pharmas:
- Jansen
- Grants:
- Corr. Author:
- Authors:
- Natalie S. Callander Rebecca Silbermann Jonathan L. Kaufman Kelly N. Godby Jacob Laubach Timothy Schmidt Douglas W. Sborov Eva Medvedova Brandi Reeves Binod Dhakal Cesar Rodriguez Saurabh Chhabra Ajai Chari Susan Bal Larry D. Anderson Jr. Bhagirathbhai R Dholaria Nitya Nathwani Parameswaran Hari Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Smith Giri Luciano J. Costa Paul G. Richardson Saad Z Usmani Peter M. Voorhees
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, LAPS-WI013, LAPS-WI020, NC002, NE003, NEWMEXICO, OR013, TN008
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- AFT-29 (GRIFFIN), MASTER
- Phases:
- 2
- Keywords: